1,575 results on '"Zeiser, Robert"'
Search Results
2. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells
3. Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
4. Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
5. Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens
6. Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis
7. 15-year remission in refractory FLT3-mutated AML attained by sorafenib
8. Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease
9. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
10. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
11. How risky is a second allogeneic stem cell transplantation?
12. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
13. Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
14. Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment
15. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease
16. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
17. Acute Graft-Versus-Host Disease
18. FDA-approved therapies for chronic GVHD
19. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
20. Evaluating the cost, cost-effectiveness and survival of an eHealth-facilitated integrated care model for allogeneic stem cell transplantation: Results of the German SMILe randomized, controlled implementation science trial
21. Immunotherapy in cancer
22. IL-23 stabilizes an effector Treg cell program in the tumor microenvironment
23. Multiomic spatial landscape of innate immune cells at human central nervous system borders
24. A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
25. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany
26. Advances in cell therapy: progress and challenges in hematological and solid tumors
27. A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy
28. Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
29. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
30. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
31. The role of the MDM2/p53 axis in antitumor immune responses
32. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
33. Granulocyte-Macrophage Colony-Stimulating Factor in Allogenic Hematopoietic Stem Cell Transplantation: From Graft-versus-Host Disease to the Graft-versus-Tumor Effect
34. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
35. CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice
36. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
37. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease
38. GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
39. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
40. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
41. Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function
42. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
43. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis
44. Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
45. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
46. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia
47. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
48. Contributors
49. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality
50. Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.